Using urine biomarkers to monitor thyroid cancer prognosis
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Well-differentiated Thyroid Cancer
This study is trying to see if tracking certain substances in urine can help doctors better understand and manage thyroid cancer in patients who have had surgery or treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 103 (estimated) |
| Ages | 20 Years to 80 Years |
| Sex | All |
| Sponsor | National Taiwan University Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Taipei) |
| Trial ID | NCT04948437 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enroll patients with thyroid cancer who have undergone thyroidectomy and/or radioactive iodine therapy to monitor urinary exosomal biomarkers, specifically thyroglobulin and galectin-3, over a two-year period. The study has already enrolled 73 patients and plans to include an additional 30 patients, focusing on differences between papillary and follicular thyroid cancers. By tracking these biomarkers, the researchers hope to develop effective treatment strategies and monitoring models for thyroid cancer progression and transformation.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with papillary, follicular, or anaplastic thyroid cancer who are undergoing post-operative follow-up.
Not a fit: Patients with unclearly diagnosed thyroid cancers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method for monitoring thyroid cancer progression and improving patient outcomes.
How similar studies have performed: Previous studies have indicated the potential of urinary biomarkers in cancer monitoring, suggesting that this approach may yield promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosed patients with thyroid papillary, follicular and anaplastic thyroid cancer, post-operation follow up Exclusion Criteria: * unclearly diagnosed patients with thyroid papillary, follicular and anaplastic thyroid cancer
Where this trial is running
Taipei
- Chih-Yuan Wang, M.D — Taipei, Taiwan (Recruiting)
Study contacts
- Principal investigator: CHIH-YUAN WANG, Doctor — Department of Internal Medicine, National Taiwan University Hospital
- Study coordinator: CHIH-YUAN WANG, Doctor
- Email: cyw1965@gmail.com
- Phone: +886-2-23123456
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.